Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin vs other SGLT2 inhibitors for sleep disorder in type 2 diabetes
jRCTs031240077Active, not recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin in type 2 diabetes mellitus (T2DM) and sleep disorder (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in overall PSQI score from baseline to week 10. Started Sep 2024; status: active, not recruiting.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)sleep disorder
Beyond the preview
Go deeper on jRCTs031240077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240077.